Phase 2, double-blind, randomized, placebo-controlled study of the safety and efficacy of elagolix in women with polycystic ovary syndrome

Objective: Evaluate the efficacy and safety of elagolix, a GnRH antagonist, to treat polycystic ovarian syndrome (PCOS). Design: A phase 2, multicenter, double-blind, randomized, placebo-controlled trial. Setting: Outpatient and academic medical centers. Patient(s): One hundred fourteen women with P...

Celý popis

Podrobná bibliografie

Hlavní autoři:	Michael C. Snabes, M.D., Ph.D., Juki Ng, Pharm.D., Ph.D., Hong Li, Ph.D., Izna Ali, Pharm.D., Ph.D., Mohamad Shebley, Ph.D., William D. Schlaff, M.D
Médium:	Artigo
Jazyk:	Inglês
Vydáno:	Elsevier 2023-06-01
Edice:	F&S Reports
Témata:	Polycystic ovarian syndrome elagolix menstrual cycle ovulation GnRH antagonist
On-line přístup:	http://www.sciencedirect.com/science/article/pii/S2666334123000156
Tagy:	Přidat tag Žádné tagy, Buďte první, kdo vytvoří štítek k tomuto záznamu!